The novel coronavious pneumonica(NCP)is considered as lung collateral disease in TCM,which is characterized by the dysfunction of immune system and the damage of deep airway and alveoli caused by inflammatory reaction,and also characterized by severe pulmonary congestion.Lianhua Qingwen is a representative treatment drug for respiratory diseases,which is guided by “Collateral Disease” theory.It has inhibitory effects on many viruses like SARS-CoV,MERS-CoV and inflammatory reactions.It has been incorporated into national and regional diagnosis and treatment programs of COVID-19,as its theoretical formulation features and basic clinical research have been widely recognized.The latest research showed that Lianhua Qingwen can inhibit activity of COVID-19 in vitro,and alleviate fever,cough,fatigue and other symptoms of NCP patients significantly.All of these have provided theoretical and research basis for the treatment of NCP with Lianhua Qingwen.